{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Biliary+Tract+Cancer&page=4",
    "query": {
      "condition": "Metastatic Biliary Tract Cancer",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 155,
    "total_pages": 16,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Biliary+Tract+Cancer&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Biliary+Tract+Cancer&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T11:48:33.806Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04234113",
      "title": "Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Thyroid Cancer",
        "Renal Cell Carcinoma",
        "Non Small Cell Lung Cancer",
        "Small-cell Lung Cancer",
        "Bladder Cancer",
        "Melanoma",
        "Merkel Cell Carcinoma",
        "Skin Squamous Cell Carcinoma",
        "Microsatellite Instability High",
        "Triple Negative Breast Cancer",
        "Mesothelioma",
        "Thymic Cancer",
        "Cervical Cancer",
        "Biliary Tract Cancer",
        "Hepatocellular Carcinoma",
        "Ovarian Cancer",
        "Gastric Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Anal Cancer"
      ],
      "interventions": [
        {
          "name": "Nanrilkefusp alfa",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SOTIO Biotech AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 115,
      "start_date": "2019-06-13",
      "completion_date": "2024-11-27",
      "has_results": true,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-11-15T11:48:33.806Z",
      "location_count": 3,
      "location_summary": "New Haven, Connecticut • Pittsburgh, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04234113"
    },
    {
      "nct_id": "NCT05506943",
      "title": "A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Biliary Tract Cancer",
        "Cholangiocarcinoma",
        "Gall Bladder Cancer",
        "Ampullary Cancer"
      ],
      "interventions": [
        {
          "name": "CTX-009",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Compass Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 168,
      "start_date": "2023-01-09",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-10",
      "last_synced_at": "2026-11-15T11:48:33.806Z",
      "location_count": 34,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05506943"
    },
    {
      "nct_id": "NCT04338685",
      "title": "A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Hepatocellular",
        "Biliary Tract Cancer",
        "Secondary Liver Cancer",
        "Liver Metastases"
      ],
      "interventions": [
        {
          "name": "RO7119929",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2020-07-16",
      "completion_date": "2023-01-09",
      "has_results": true,
      "last_update_posted_date": "2024-12-09",
      "last_synced_at": "2026-11-15T11:48:33.806Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04338685"
    },
    {
      "nct_id": "NCT02714374",
      "title": "GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Organ Cancers"
      ],
      "interventions": [
        {
          "name": "GL-ONC1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Andrew Lowy",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2016-03-25",
      "completion_date": "2019-08-06",
      "has_results": false,
      "last_update_posted_date": "2024-08-06",
      "last_synced_at": "2026-11-15T11:48:33.806Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02714374"
    },
    {
      "nct_id": "NCT07020221",
      "title": "A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma",
        "Non Small Cell Lung Cancer",
        "Colorectal Cancer",
        "Solid Tumor, Adult",
        "G12D Mutated KRAS"
      ],
      "interventions": [
        {
          "name": "VS-7375",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin + Pemetrexed + Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine + Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Defactinib",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Repaglinide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Verastem, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 616,
      "start_date": "2025-06-24",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-11-10",
      "last_synced_at": "2026-11-15T11:48:33.806Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07020221"
    },
    {
      "nct_id": "NCT07277413",
      "title": "A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "NSCLC Adenocarcinoma",
        "Gastroesophageal Cancer (GC)",
        "Gastric Adenocarcinoma",
        "Adenocarcinoma of Esophagus",
        "Squamous Cell Car. - Esophagus",
        "Urothelial Carcinoma (UC)",
        "Bladder Cancer",
        "Mesothelioma",
        "Pleural Mesothelioma",
        "Peritoneal Mesothelioma",
        "Non-Small Cell Lung Cancer NSCLC",
        "Pancreatic Cancer",
        "Biliary Tract Carcinoma"
      ],
      "interventions": [
        {
          "name": "IDE892",
          "type": "DRUG"
        },
        {
          "name": "IDE397",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IDEAYA Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 260,
      "start_date": "2026-03-04",
      "completion_date": "2028-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-11-15T11:48:33.806Z",
      "location_count": 23,
      "location_summary": "Goodyear, Arizona • Phoenix, Arizona • Duarte, California + 19 more",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07277413"
    },
    {
      "nct_id": "NCT02856568",
      "title": "Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Resectable Cholangiocarcinoma",
        "Recurrent Cholangiocarcinoma",
        "Stage III Extrahepatic Bile Duct Cancer",
        "Stage III Intrahepatic Cholangiocarcinoma",
        "Stage IIIA Hilar Cholangiocarcinoma",
        "Stage IIIB Hilar Cholangiocarcinoma",
        "Stage IVA Extrahepatic Bile Duct Cancer",
        "Stage IVA Hilar Cholangiocarcinoma",
        "Stage IVA Intrahepatic Cholangiocarcinoma",
        "Stage IVB Extrahepatic Bile Duct Cancer",
        "Stage IVB Hilar Cholangiocarcinoma",
        "Stage IVB Intrahepatic Cholangiocarcinoma",
        "Unresectable Extrahepatic Bile Duct Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Ricolinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2017-05-01",
      "completion_date": "2021-10",
      "has_results": false,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-11-15T11:48:33.806Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02856568"
    },
    {
      "nct_id": "NCT07780838",
      "title": "Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Ampulla of Vater Carcinoma",
        "Locally Advanced Biliary Tract Carcinoma",
        "Locally Advanced Extrahepatic Cholangiocarcinoma",
        "Locally Advanced Gallbladder Carcinoma",
        "Locally Advanced Intrahepatic Cholangiocarcinoma",
        "Metastatic Ampulla of Vater Carcinoma",
        "Metastatic Biliary Tract Carcinoma",
        "Metastatic Extrahepatic Cholangiocarcinoma",
        "Metastatic Gallbladder Carcinoma",
        "Metastatic Intrahepatic Cholangiocarcinoma",
        "Stage III Ampulla of Vater Cancer AJCC v8",
        "Stage III Distal Bile Duct Cancer AJCC v8",
        "Stage III Gallbladder Cancer AJCC v8",
        "Stage III Intrahepatic Cholangiocarcinoma AJCC v8",
        "Stage IV Ampulla of Vater Cancer AJCC v8",
        "Stage IV Distal Bile Duct Cancer AJCC v8",
        "Stage IV Gallbladder Cancer AJCC v8",
        "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8",
        "Unresectable Ampulla of Vater Carcinoma",
        "Unresectable Biliary Tract Carcinoma",
        "Unresectable Extrahepatic Cholangiocarcinoma",
        "Unresectable Gallbladder Carcinoma",
        "Unresectable Intrahepatic Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pemigatinib",
          "type": "DRUG"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2026-11-01",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-11-15T11:48:33.806Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07780838"
    },
    {
      "nct_id": "NCT00096083",
      "title": "Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "isolated perfusion",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Delcath Systems Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2004-09",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2013-10-23",
      "last_synced_at": "2026-11-15T11:48:33.806Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00096083"
    },
    {
      "nct_id": "NCT07021066",
      "title": "Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastric Adenocarcinoma",
        "Advanced Pancreatic Ductal Adenocarcinoma",
        "Esophageal Adenocarcinoma",
        "Biliary Tract Cancer",
        "Other Solid Tumors"
      ],
      "interventions": [
        {
          "name": "BL-M05D1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SystImmune Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2025-07-30",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-05",
      "last_synced_at": "2026-11-15T11:48:33.806Z",
      "location_count": 11,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07021066"
    }
  ]
}